Aims: To assess the accuracy and precision of measuring haemoglobin A 2 by high performance liquid chromatography (HPLC) in the presence and absence of sickle cell trait, with or without a thalassaemia trait. Methods: The haemoglobin A 2 percentage and the haemoglobin A 2 plus S percentages were determined by HPLC on 82 normal controls and 78 patients with sickle cell trait, respectively; the a thalassaemia status of each patient was determined by polymerase chain reaction. Red cell indices and haemoglobin A 2 and S percentages were compared in patients with two, three, or four a genes. Results: Of the 78 patients with sickle cell trait, 17 were heterozygous for a + thalassaemia (2a 3.7 /aa) and 13 were homozygous (2a 3.7 /2a 3.7 ). Microcolumn chromatography showed that the haemoglobin A 2 percentage was slightly, but significantly, higher than normal in sickle cell trait. HPLC determinations of haemoglobin A 2 percentage in patients with sickle cell trait are precise but inaccurate, the percentage being appreciably overestimated. The measured haemoglobin A 2 percentage is stable for one week, but inaccuracy increases by two weeks in most samples. Despite this inaccuracy, there are significant differences in the HPLC ''haemoglobin A 2 percentage'' between groups of individuals with two, three, and four a genes. Conclusions: Haemoglobin A 2 determinations by HPLC are precise but inaccurate. Nevertheless, there are significant differences in the haemoglobin A 2 percentage in subjects with two, three, and four a genes. Although there is some overlap between groups, this can be useful, together with the red cell indices, in predicting the likelihood of coexisting a thalassaemia. H aemoglobin A 2 can be measured by several laboratory methods of varying accuracy and precision. The principal reason for measuring A 2 is for the diagnosis of b thalassaemia trait and, for this purpose, methods that are considered sufficiently precise for diagnosis include cation exchange high performance liquid chromatography (HPLC), microcolumn chromatography, and cellulose acetate electrophoresis with elution. Cellulose acetate electrophoresis followed by scanning densitometry is thought to be too imprecise for this purpose. Although the diagnosis of b thalassaemia trait is the main reason for the measurement of haemoglobin A 2 , the A 2 percentage is also affected by other factors. Both iron deficiency and a thalassaemia trait are known to lower the percentage, whereas the percentage has been reported to be increased in individuals with sickle cell trait, 
H aemoglobin A 2 can be measured by several laboratory methods of varying accuracy and precision. The principal reason for measuring A 2 is for the diagnosis of b thalassaemia trait and, for this purpose, methods that are considered sufficiently precise for diagnosis include cation exchange high performance liquid chromatography (HPLC), microcolumn chromatography, and cellulose acetate electrophoresis with elution. Cellulose acetate electrophoresis followed by scanning densitometry is thought to be too imprecise for this purpose. Although the diagnosis of b thalassaemia trait is the main reason for the measurement of haemoglobin A 2 , the A 2 percentage is also affected by other factors. Both iron deficiency and a thalassaemia trait are known to lower the percentage, whereas the percentage has been reported to be increased in individuals with sickle cell trait, 2 and it is thought that this may be of some use in diagnosis.
''The degree of inaccuracy of haemoglobin S and A 2 percentages by high performance liquid chromatography and whether this interferes with their diagnostic usefulness has not been determined previously''
The haemoglobin S percentage is usually measured to distinguish between sickle cell anaemia or sickle cell/b 0 thalassaemia (haemoglobin S usually greater than 90%), sickle cell/b + thalassaemia (haemoglobin S more than 50%), and sickle cell trait (haemoglobin S less than 50%); making these distinctions does not require a particularly precise assay because differences are usually clear cut. In addition, the percentage of haemoglobin S may be useful in predicting whether an individual with sickle cell trait has coexisting a thalassaemia trait. A lower haemoglobin S percentage is seen if one of the four a genes is deleted and lower still if two of the four a genes are deleted. This results from the negatively charged b A having a greater affinity than the positively charged b S for the reduced amount of positively charged a chain present. For indicating the likely presence of a thalassaemia trait, the assay should be more precise because otherwise increasing overlap between groups will probably occur.
Previous observations on haemoglobin S and A 2 percentages have generally been based on cellulose acetate electrophoresis and microcolumn chromatography. However, increasingly, normal and variant haemoglobins are being measured by HPLC. This technique has been shown, in a small number of patient samples, to overestimate the haemoglobin A 2 percentage in the presence of haemoglobin S. 3 This is because some haemoglobin S that has undergone post-translational modification has the same retention time as haemoglobin A 2 , and thus is measured along with it. In addition, glycosylated haemoglobin S has the same retention time as haemoglobin A, so that it is also measured with haemoglobin A when both haemoglobins are present. The degree of inaccuracy of haemoglobin S and A 2 percentages by HPLC and whether this interferes with their diagnostic usefulness has not been determined previously. Therefore, we studied the accuracy and precision of estimates of the haemoglobin A 2 percentage by three methods in patients with haemoglobin S, and also studied the effect of aging of the sample on any inaccuracy.
In addition, we determined the a gene status of the patients with sickle cell trait and related the S and A 2 percentages, as determined by different techniques, to the number of a genes present.
MATERIALS AND METHODS
All investigations were performed on EDTA anticoagulated venous blood samples, either from healthy volunteers or from patients in whom haemoglobinopathy investigations had been requested. In the case of patient samples, that part of the blood sample remaining when all necessary diagnostic tests had been performed was used for our study.
A full blood count and HPLC analysis were performed on the samples from healthy volunteers, mainly of northern European origin. Data derived from volunteers with normal haemoglobin concentrations and red blood cell indices were used to establish a reference range for the haemoglobin A 2 percentage.
Patient samples were studied by HPLC on a Bio-Rad Variant 2 instrument (Bio-Rad Laboratories, Hemel Hempstead, Hertfordshire, UK) using the b thalassaemia short programme. Haemoglobins A, A 2 , and S were measured by microcolumn chromatography using a Helena Sickle-Thal QUIK column kit. Cellulose acetate electrophoresis at pH 8.2-8.6 was performed on Helena Titan III cellulose acetate plates and haemoglobins A, S, and A 2 were then measured by scanning densitometry. A sickle solubility test was performed on all samples with variant haemoglobin, using Lorne Sicklechek. A full blood count was performed on a Coulter Gen S automated counter. Serum ferritin was estimated when red blood cell indices suggested possible coexisting iron deficiency. Patient samples were considered to contain haemoglobin S when there was a variant haemoglobin with an appropriate retention time and the sickle solubility test was positive. A diagnosis of sickle cell trait was made if patients had both haemoglobin A and haemoglobin S, with the proportion of haemoglobin A being greater than that of haemoglobin S. A diagnosis of sickle cell anaemia was made only if haemoglobins S, F, and A 2 were present and if the mean cell volume and mean cell haemoglobin were normal or near normal, thus excluding S/b 0 thalassaemia compound heterozygosity.
All patients with sickle cell trait were investigated by the polymerase chain reaction (PCR) 4 to identify heterozygosity (2a 3.7 /aa) or homozygosity (2a 3.7 /2a 3.7 ) for 2a 3.7 , the a + thalassaemia determinant which is present in about 25-30% of Afro-Caribbeans (1-2% being homozygotes). A similar or higher frequency of this variant is seen in West Africans, who comprised most of our African patients. Haemoglobin S and A 2 percentages and red blood cell indices were compared in patients with sickle cell trait with and without a thalassaemia trait, and an algorithm was devised to help distinguish those with a thalassaemia trait from those with four a genes.
RESULTS
We studied 82 healthy volunteers and 78 patients with sickle cell trait, with or without a thalassaemia trait. PCR analysis showed that 17 of the patients were heterozygous for a + thalassaemia (2a 3.7 /aa) and 13 were homozygous
). One patient with red blood cell indices strongly suggestive of thalassaemia trait did not have either b thalassaemia or 2a 3.7 , and further investigation did not disclose a 0 thalassaemia; it was thought that he probably had some type of a thalassaemia, possibly non-deletional, but because this could not be determined he was excluded from further analysis. The remaining 47 patients were assessed as likely to have four a genes because other a thalassaemia determinants are uncommon in this population. Four of the patients with sickle cell trait and normal a genes were found to have coexisting iron deficiency anaemia.
The data for haemoglobin A 2 percentages in 82 healthy volunteers with normal red cell indices showed a Gaussian distribution. The observed range of haemoglobin A 2 was from 2.4% to 3.3%, with a mean of 2.8%, and a 95% range of 2.4-3.2%. This compares with a range of 2.3-3.5% previously derived in our laboratory using microcolumn chromatography.
The precision of the estimates of the haemoglobin A 2 percentage in the presence of haemoglobin S for the three methods studied was determined by means of duplicate observations; table 1 shows the results. Precision was best with HPLC, intermediate with microcolumn chromatography, and (as expected) considerably worse with scanning densitometry.
The haemoglobin A 2 percentage was measured by HPLC, microcolumn chromatography, and scanning densitometry in 73 patients with sickle cell trait without iron deficiency. Table 2 shows the results. As expected, the standard deviation was greatest when scanning densitometry was used, but the mean values by scanning densitometry and microcolumn chromatography were very similar, 3.3% and 3.6%, respectively (p . 0.05), supporting the accuracy of the microcolumn chromatography methodology. In contrast, the mean value by HPLC was 4.4%. HPLC measurements were significantly higher than microcolumn chromatography (p , 0.001) or scanning densitometry (p , 0.01) measurements, whereas the last two methods did not differ from one another (p . 0.1). Not surprisingly, the degree of overestimation of haemoglobin A 2 by HPLC, in comparison with microcolumn chromatography, correlated significantly (albeit weakly) with the percentage of haemoglobin S in the specimen (r = 0.28; p , 0.05).
When measured by microcolumn chromatography, the mean value of haemoglobin A 2 in the 73 patients with sickle cell trait without iron deficiency was significantly higher than that in normal individuals, whose haemoglobin A 2 values had been estimated by HPLC (3.3% in comparison with 2.8%; p , 0.05). A similar difference from normal was seen for the mean haemoglobin A 2 by scanning densitometry (3.6% in comparison with 2.8%) but, because of the greater scatter, this was not significant (p . 0.1). In contrast to these slightly higher mean values, haemoglobin A 2 as measured by HPLC was considerably higher in subjects with sickle cell trait than in normal individuals, reflecting the inaccuracy of measurements in the patients with sickle cell trait (mean values 4.4% and 2.8%, respectively; p , 0.01). The degree of overestimation of haemoglobin A 2 in 22 samples from subjects with sickle cell trait was stable for one week, but in 15 of these samples increased between one and two weeks; mean values when fresh and at two weeks were 4.5% and 5.1%, respectively (p , 0.05). Samples from four patients with sickle cell anaemia showed an even greater increase in apparent haemoglobin A 2 by two weeks, whereas in 12 normal subjects there was no change in haemoglobin A 2 estimates (data not shown). In contrast to the increasing inaccuracy of HPLC estimates of haemoglobin A 2 with aging in samples containing haemoglobin S, estimates in 12 such samples by microcolumn chromatography were stable for two weeks (data not shown). Figure 1 shows the haemoglobin S percentage in groups with two, three, and four a genes and tables 3-5 summarise the results (excluding the four patients with iron deficiency) in comparison with previously published data.
An algorithm was devised to aid in separating those with two or three a genes from those with a full complement of four a genes (fig 2) . Using this algorithm, all 12 patients with 2a/2a were identified and no other individuals were misassigned to this group. Of 16 individuals with 2a/aa, 11 were correctly identified, with only four of 45 individuals with aa/aa being misassigned.
DISCUSSION
The reference range for haemoglobin A 2 by HPLC using the Biorad Variant 2 instrument is comparable with our previous reference range derived by microcolumn chromatography. However, it appears to differ appreciably from a reference range derived from 104 subjects with normal red blood cell indices studied on the Biorad Variant; the mean in that study was 2.4% and the 95% range 1.9-3.0%, 11 emphasising the importance of each laboratory deriving a reference range for the specific instrument and method used.
We have shown that estimates of haemoglobin A 2 percentage by microcolumn chromatography are precise and accurate in samples from patients with sickle cell trait, and have confirmed previous observations that haemoglobin A 2 percentage is slightly but significantly higher in sickle cell trait. We have also confirmed that estimates of haemoglobin A 2 by HPLC are inaccurate in the presence of haemoglobin S, even though the precision is high. The mean observed difference between microcolumn chromatography and HPLC was 1.1%, and the mean observed difference between scanning densitometry and HPLC was 0.8%. Because the degree of inaccuracy was related to the amount of haemoglobin S present, it can be predicted that the degree of inaccuracy will be greater in patients with sickle cell anaemia or sickle cell/b thalassaemia than in those with sickle cell trait.
''Estimates of haemoglobin A 2 by high performance liquid chromatography are inaccurate in the presence of haemoglobin S, even though the precision is high''
The degree of inaccuracy of haemoglobin A 2 estimates in patients with sickle cell trait does not increase if the sample is stored for up to one week but, after two weeks of storage, an increase is seen. In the absence of haemoglobin S, HPLC estimates of haemoglobin A 2 are stable for at least two weeks. Our observations of a storage effect in the presence of haemoglobin S confirm the observations of Suh et al, which were based on only three samples. 3 If the haemoglobin A 2 percentage, as measured by HPLC, were to be used to predict whether a patient had sickle cell anaemia or sickle cell/b 0 thalassaemia it would be necessary to determine the percentage of apparent haemoglobin A 2 seen in these two conditions, rather than extrapolating from percentages obtained by more accurate methods. In addition, it would be important to measure the percentage within one week of obtaining the sample. A corollary of the overestimation of haemoglobin A 2 by HPLC in individuals with sickle cell trait is that haemoglobin S is underestimated. However, because the error is proportionately much lower, this is of no practical importance. The trimodal distribution of haemoglobin S percentages, attributable to the presence of two, three, or four a genes is still apparent when the haemoglobin S percentage is measured by HPLC, and the overlap between the three groups is similar to that seen with more accurate techniques.
Normally, the a chain is present in excess. However, when a thalassaemia coexists with sickle cell trait, the amount of a chain available becomes rate limiting, and the positively charged a chain combines preferentially with the negatively charged b
A chain, rather than with the positively charged b S chain, with a consequent reduction in the haemoglobin S percentage. The d chain is also positively charged, so that the a chain is likely to combine preferentially with b A , rather than with d. Haemoglobin A 2 has been reported to be higher in patients with sickle cell anaemia who also have a thalassaemia than in those who do not, 12 13 suggesting that, when the amount of a chain is rate limiting, combination with the d chain is favoured over combination with b S . These observations suggest that the affinity of nona chains for the a chain is b A . d . b S . Data from two previous studies, those of Whitten and Rucknagel 1 and of Wong et al, 8 suggest that haemoglobin A 2 is higher in patients with sickle cell trait and a thalassaemia than in those with sickle cell trait without a thalassaemia, whereas El-Hazmi 9 found no differences. Our data confirm the first two studies because we found a significantly higher haemoglobin A 2 percentage in patients with two deleted a genes than in those with four a genes. This suggests that, when there are insufficient a chains but b ''Our algorithm enables most cases to be recognised, with only a minority of those with four a genes being misassigned''
In conclusion, our data show that despite the inaccuracy inherent in the measurement of haemoglobin A 2 by HPLC, the percentages of haemoglobins A, A 2 , and S in patients with sickle cell trait can nevertheless be used, together with the red blood cell indices, to predict the presence of coexisting a thalassaemia trait, with the overlap between groups being similar to that seen with more accurate techniques. The algorithm we have devised correctly identified all patients with deletion of two of four a genes without misassigning other individuals to this group. No algorithm based on haematological variables is likely to permit the recognition of all individuals with deletion of a single a gene because some of these individuals have completely normal red blood cell indices and, as we have shown, their haemoglobin S percentages show some overlap with the values seen in individuals with four a genes. However, our algorithm enables most cases to be recognised, with only a minority of those with four a genes being misassigned. This permits the haematology laboratory to give useful advice to clinical staff as to the probable cause of microcytosis. 
